Everything below concerns REV-ERB. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
== Soundtrack == The film's soundtrack album was released by Deadmau5 on January 25, 2019, through his record label Mau5trap. The soundtrack's release details were announced on January 8, 2019, along with the film's initial trailer. A single from the soundtrack album, "Midas Heel" was released on January 11, 2019, followed by the vocal version called "Drama Free" featuring Lights which was previously released on Mau5ville: Level 2. Several tracks of the score (such as "Somb", "Wilhelm" and "End") feature elements from Deadmau5's previous tracks from his seventh studio album While(1<2), as well as two new tracks named "Nosedive" and "Camilla", the former being a remake of his unreleased track "Rio", the latter being known previously as "Suite 02". Elements of "Nosedive" would later be reused in his 2023 track "Input Output" as well.
== Therapeutic benefits == The feasibility of using lactic acid bacteria (LAB) as functional protein delivery vectors has been widely investigated. Lactococcus lactis has been demonstrated to be a promising candidate for the delivery of functional proteins because of its noninvasive and nonpathogenic characteristics. Many different expression systems of L. lactis have been developed and used for heterologous protein expression.
=== Digestive system === Arenobufagin has shown to cause appoptose in hepatocellular carcinoma cells in mice, although this method is not used to cure hepatocellular carcinoma in modern human medicine.
Heroin from Afghanistan enters East Africa through the Swahili Coast, from the Indian Ocean. Many of the countries in East Africa affected by drug trafficking along the southern route have high poverty levels, poor governance and security challenges. This is exacerbated by ongoing tensions and conflicts within the region, making these states especially vulnerable to organised crime and the threat of exploitation that these criminal groups pose. Heroin seizures have indicated an increase in drug flow to the region, and further utilisation of the southern route. This has led to a growth in drug use and a rise in drug injecting in countries such as Mauritius, South Africa, Nigeria and Kenya. Opiates often reach East African on dhows, which are traditional trading ships originating in Arab and South Asian countries. Dhows used for smuggling have been caught carrying up to 1,000 kg of heroin. These East African countries do have their own consumer markets for drugs, but they are also heavily used as trans-shipment ports for routes which continue onwards e.g. to Europe.
Sources: en.wikipedia.org
Overlapping peptide libraries - in which the entirety of a larger protein is used to produce a library of 8-20 amino acid peptides which overlap; these libraries can be used to identify the specific regions of a larger protein which participate in a given interaction or to provide pre-digested versions of a larger protein for binding. Truncation peptide libraries - in which a given peptide is produced with various or all N or C terminal truncations, these smaller fragments can be used to identify the minimal required region of a peptide for a given interaction being studied. Random libraries - randomly generated peptides of a set length, or range of lengths, can be used to identify novel binding partners of a target of interest. Alanine scanning libraries - in which each amino acid of a given protein or peptide is replaced with an alanine sequentially such that each peptide contains only one alanine mutations but all possible mutations to alanine are present; this can be used to identify critical residues for binding Positional or scrambled peptide libraries - in which specific positions in the peptide are substituted for many or all other amino acids such that the effect of each amino acid at that position in the peptide on the binding or other activity of the peptide can be tested. Scrambled libraries are often random peptides and used as negative controls. Solid phase peptide synthesis is limited to a peptide chain length of approximately 70 amino acids and is generally unsuitable for the study of larger proteins.
=== Hydrocodone === Mechanism of action: Hydrocodone acts primarily as an agonist at the mu-opioid receptors, but is also a weak agonist against the delta opioid and kappa opioid receptors. Absorption/distribution: The oral formulation can be absorbed from the gastrointestinal tract and remain 20–50% bound to plasma proteins. The onset of analgesia is about 20 to 30 minutes with a duration of 4 to 8 hours and t1/2 of 3 to 4 hours. Maximum serum levels are achieved at 1.3 hours. Metabolism/excretion: It is metabolized to norhydrocodone by cytochrome P450 3A4 and to hydromorphone, also biologically active, by cytochrome P450 2D6. For individuals who have a defect in the gene encoding CYP2D6, the clearance of the drug will be lower and less metabolite such as hydromorphone will be formed; however, the effect on analgesia remains unknown. Metabolites: Hydromorphone, the major active metabolite, has a 10-33-fold higher binding affinity for the mu-opioid receptor than hydrocodone. It may be up to >100-fold higher in some patients.
=== Regulatory status === Selegiline is a prescription drug. It is not specifically a controlled substance in the United States and hence is not an illegal drug. However, deprenyl and selegiline are controlled substances in Japan. They are classified as "Stimulants", alongside a variety of other amphetamines, under Article 2 of Japan's Narcotics and Psychotropics Control Law. Selegiline is known to metabolize into small amounts of levoamphetamine and levomethamphetamine but is thought to have little to no misuse potential or dependence liability.
== History == The orexin neuropeptides were discovered in 1998 and the role of the orexin system in the etiology of narcolepsy was identified between 1999 and 2000. Subsequent research further established the role of the orexin system in sleep–wake regulation. Due to the promising potential of orexin system modulation in the treatment of sleep disorders, these findings led to translational efforts to bring orexin receptor modulators to medicine as therapeutic agents. Suvorexant was developed by Merck. It entered clinical development in 2006 and was first described in the medical literature in 2010. The medication was approved by the FDA for the treatment of insomnia in the United States on 13 August 2014. Suvorexant was initially released November 2014 in Japan, then later reached the United States in February 2015, Australia in November 2016, and Canada in November 2018. It was the first orexin receptor antagonist to be introduced for medical use, and was followed by lemborexant in 2019 and daridorexant in 2022. Development of almorexant (ACT-078573) and filorexant (MK-6096) was discontinued, while seltorexant (MIN-202, JNJ-42847922) and vornorexant (ORN-0829, TS-142) are still in clinical trials. Suvorexant marketing exclusivity in the United States was set to expire in January 2023 and patent protection is set to expire in 2029 to 2033.
=== Conflict === Channel conflict can arise when one intermediary's actions prevent another intermediary from achieving their objectives. Vertical channel conflict occurs between the levels within a channel, and horizontal channel conflict occurs between intermediaries at the same level within a channel. Channel conflict is a perennial problem. There are risks that a powerful channel member may coordinate the interests of the channel for personal gain. Territories are often seen as a source of conflict, sometimes because boundaries are only loosely defined.
Sources: en.wikipedia.org
The leveraged buyout of Electronic Arts is completed, with a consortium led by Saudi Arabia's Public Investment Fund and including Silver Lake and Affinity Partners acquiring the American video game publisher for US$55 billion and taking it private. The transaction is the largest leveraged buyout in history. The Senate confirms Dr. Erica Schwartz as the director of the Centers for Disease Control and Prevention to succeed acting director Dr. Jay Bhattacharya. August 6 A Republican-led US Senate committee votes to hold former Chief Medical Advisor to the President Anthony Fauci in contempt of Congress, escalating efforts to blame him for potential COVID-19 pandemic mistakes. United States Senator Mitch McConnell is discharged from a rehabilitation center after more than seven weeks of recovery following a June hospitalization. He will continue recovering at home while remaining away from the Senate. A judge in New Mexico orders Meta Platforms to pay an additional $567 million in penalties over five years for liability in knowingly harming children's mental health. August 7 A sweeping Russia sanctions bill negotiated by the late Senator Lindsey Graham is passed by the Senate to force Russian President Vladimir Putin to end the Russo-Ukrainian war. US opens test ranges for small companies to receive munitions faster. Former U.S. president Joe Biden's son Hunter says in a BBC interview that Biden's prostate cancer has metastasized into his bones and further. August 8 The Senate confirms Todd Blanche as the United States attorney general to succeed Pam Bondi.
== Health concerns == Uranium emits alpha radiation, so external exposure has limited effect. Significant internal exposure to tiny particles of uranium or its decay products, such as thorium-230, radium-226 and radon-222, can cause severe health effects, such as cancer of the bone or liver. Uranium is also chemically toxic, meaning that ingestion of uranium can cause kidney damage from its chemical properties much sooner than its radioactive properties would cause cancers of the bone or liver.
However, other smaller pharmaceutical companies also produce insulin, such as Mannkind (Afrezza), Viatris (Semglee), Lupin (Lupisulin), Baxter (Myxredlin), Biocon (Basalog), Darou Pakhsh (Dipisulin), Glenmark (Insulong), Wockhardt (Wosulin), Julphar (Jusline), SciGen (SciLin), Bioton (Gensulin), and Cadila (Humanext). Many insulin analogues are available unbranded.
On 1 July 2009, the Hydropower Corps officially became part of China's emergency management system as a disaster relief agency. The 3rd Hyrdopower Detachment's Search and Rescue Company was established in August 2013 and was the elite unit of the Hydropower Corps dedicated to Urban Search and Rescue.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.